These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9754892)

  • 1. Clinical evaluation of new global clotting assay for monitoring of LMWH treatment: pilot study.
    Makris PE; Pithara E
    Int Angiol; 1998 Jun; 17(2):69-79. PubMed ID: 9754892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monitoring of plasma concentration of low molecular weight heparin--comparative evaluation with chromogenic and clotting assays].
    Katagiri H; Itoh S; Uchida T; Kawai Y; Watanabe K
    Rinsho Byori; 1999 Nov; 47(11):1046-51. PubMed ID: 10590682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessing the use of low-molecular-weight heparins fo venous thromboembolism prophylaxis in internal medicine patients].
    Villar Fernández I; Urbieta Sanz E; Arenere Mendoza M; López Larramona G; Marcilla Córdoba F; Rabanaque Hernández MJ
    Farm Hosp; 2004; 28(6):402-9. PubMed ID: 15628942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low molecular weight heparin on clot rate and activated clotting time: an in vitro study.
    Shi XB; Bai Y; Li J; Xiao J; Wang JQ; Zheng H
    Chin Med J (Engl); 2013; 126(18):3553-6. PubMed ID: 24034107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sensitivity of new reagents for laboratory monitoring of low molecular weight heparin: an in vitro study].
    Shi XB; Wang JQ; Wang JY; Hou XX; Ma ZM
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(22):1566-8. PubMed ID: 21914372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD; Brandenburg VM; Lanzmich R; Floege J
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses.
    Despotis GJ; Alsoufiev AL; Spitznagel E; Goodnough LT; Lappas DG
    Ann Thorac Surg; 1996 Mar; 61(3):795-9. PubMed ID: 8619695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
    Konstantinidis K; Gerasimidis T; Verdy E; Elalamy I; Samama MM; Gerotziafas GT
    Thromb Haemost; 2007 Jan; 97(1):109-18. PubMed ID: 17200777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
    Kitchen S; Iampietro R; Woolley AM; Preston FE
    Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
    Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
    Ao PY; Hawthorne WJ; Coombs R; Fletcher JP
    Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and prevention of venous thromboembolism.
    Hull RD; Pineo GF; Valentine KA
    Semin Thromb Hemost; 1998; 24 Suppl 1():21-31. PubMed ID: 9840689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin).
    Toulon P; Ajzenberg N; Smahi M; Guillin MC
    Thromb Res; 2007; 119(2):135-43. PubMed ID: 16426667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
    Burris HA
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S3-16; quiz S41-2. PubMed ID: 16638456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.